Skip to content

7 days to go

Healthcare Investment Access (HIA) Program

25.11.2025 - 26.03.2026

Location: New York, USA

Seminar

HIA is a high-impact program designed to elevate Nordic healthcare companies onto the global stage, with a strong emphasis on unlocking opportunities in the US capital markets.

Programme elements

Application is now closed. If you still wish to enquire about participation or have any questions, please contact the team members listed below. We will do our best to assist where possible.

Participation rates

  • Healthcare Investment Access (HIA) Program

    Registration deadline: 3 November 2025
    • Participation feeThe participation fee will only be charged to companies selected for the program.
      $1,500.00 *
      $1,500.00 *

* Prices exclude VAT

Event terms
Healthcare Investment Access program

Sharpen your pitch, elevate your presence and step into the spotlight.

HIA is a high-impact program designed to elevate Nordic healthcare companies onto the global stage, with a strong emphasis on unlocking opportunities in the U.S. capital markets.

Program Highlights:

  • Connect directly with leading international investors, venture funds, and strategic partners.
  • Gain expert guidance on how to position your company for global capital engagement, with tailored insights into investor expectations outside the Nordic region.
  • Initial 360° Review & Mentoring — Comprehensive, multi-disciplinary evaluations covering clinical, commercial, regulatory, and financing dimensions. These reviews identify blind spots, align strategic priorities, and sharpen investor readiness. Followed by two hours of mentoring with seasoned operators and investors. Focused on narrative development, milestone planning, and market-entry strategies to elevate professionalism and execution.
  • Learn how to craft compelling pitches and sharpen your messaging for U.S. and European audiences.
  • Maximize visibility through curated investor interactions and spotlight appearances at premier events: including the DNB Carnegie Nordic Healthcare Conference in Oslo, a strategically curated European Healthcare Investor Forum in Zurich and the Nordic-American Healthcare Conference in NY.
  • Selected companies will be eligible for a stipend to help assist with travel and external advisory needs.

Who Should Apply:

  • Nordic healthcare companies led by a CEO or senior executive.
  • Teams with at least a Minimum Viable Product (MVP) ready for clinical feedback.
  • Companies with no current U.S. market presence, but a clear ambition to scale internationally.
  • Ventures with a strong value proposition and readiness to engage global stakeholders.

Program Timeline:

  • Nov 3rd: Application deadline
  • Nov 25: Launch and pitch event in Oslo at the DNB Carnegie Nordic Healthcare Conference
  • Dec–Mar: Individual investor readiness workshops, training and positioning sessions
  • Feb (tbd): European Healthcare Investor Forum in Zurich
  • Mar 23–26: Market visit to New York, including pitch events and stakeholder meetings

Apply Now: Don’t miss this chance to accelerate your growth and make a meaningful impact in the U.S. and Global healthcare markets.

Practical information

For more information, please contact our team:

Zacharias Holm

Senior Advisor, Innovation Norway

Send email

Andreas Dirnagl

Senior Advisor, Healthcare DNB Bank

Send email

Jutta Heix

Head of International Affairs, OCC

Send email

Organisers

INNOVATION NORWAY

Website

DNB // BACKBAY

Website

Partners

OSLO CANCER CLUSTER

Website

Important conditions

Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.

Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.

Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.